WO2019203755A3 - Forme pharmaceutique orale solide comprenant de la linagliptine - Google Patents

Forme pharmaceutique orale solide comprenant de la linagliptine Download PDF

Info

Publication number
WO2019203755A3
WO2019203755A3 PCT/TR2018/050812 TR2018050812W WO2019203755A3 WO 2019203755 A3 WO2019203755 A3 WO 2019203755A3 TR 2018050812 W TR2018050812 W TR 2018050812W WO 2019203755 A3 WO2019203755 A3 WO 2019203755A3
Authority
WO
WIPO (PCT)
Prior art keywords
linagliptin
dosage form
oral dosage
solid oral
binder
Prior art date
Application number
PCT/TR2018/050812
Other languages
English (en)
Other versions
WO2019203755A2 (fr
Inventor
Ali TÜRKYILMAZ
Nur PEHLIVAN AKALIN
Merve ERGUN DONMEZ
Original Assignee
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi filed Critical Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority to CA3085455A priority Critical patent/CA3085455C/fr
Priority to EP18914956.0A priority patent/EP3723761A4/fr
Publication of WO2019203755A2 publication Critical patent/WO2019203755A2/fr
Publication of WO2019203755A3 publication Critical patent/WO2019203755A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une forme pharmaceutique orale solide comprenant de la linagliptine et au moins un liant.
PCT/TR2018/050812 2017-12-15 2018-12-14 Forme pharmaceutique orale solide comprenant de la linagliptine WO2019203755A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA3085455A CA3085455C (fr) 2017-12-15 2018-12-14 Forme pharmaceutique orale solide comprenant de la linagliptine
EP18914956.0A EP3723761A4 (fr) 2017-12-15 2018-12-14 Forme pharmaceutique orale solide comprenant de la linagliptine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2017/20515 2017-12-15
TR2017/20515A TR201720515A2 (tr) 2017-12-15 2017-12-15 Li̇nagli̇pti̇n i̇çeren bi̇r kati oral dozaj formu

Publications (2)

Publication Number Publication Date
WO2019203755A2 WO2019203755A2 (fr) 2019-10-24
WO2019203755A3 true WO2019203755A3 (fr) 2020-01-16

Family

ID=67900883

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2018/050812 WO2019203755A2 (fr) 2017-12-15 2018-12-14 Forme pharmaceutique orale solide comprenant de la linagliptine

Country Status (4)

Country Link
EP (1) EP3723761A4 (fr)
CA (1) CA3085455C (fr)
TR (1) TR201720515A2 (fr)
WO (1) WO2019203755A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022173406A1 (fr) * 2021-02-15 2022-08-18 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Procédé pour formulations de linagliptine ou d'un sel pharmaceutiquement acceptable de celle-ci

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106138059A (zh) * 2015-03-27 2016-11-23 天津汉瑞药业有限公司 一种稳定的利格列汀药物组合物
EP3156048A1 (fr) * 2015-10-13 2017-04-19 Galenicum Health S.L. Composition pharmaceutique stable de linagliptine sous forme de comprimé à libération immédiate

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32427A (es) * 2009-02-13 2010-09-30 Boheringer Ingelheim Internat Gmbh Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
WO2013128379A2 (fr) 2012-02-27 2013-09-06 Dr. Reddy's Laboratories Limited Formes polymorphes cristallines de linagliptine
EP2908806A1 (fr) * 2012-10-09 2015-08-26 Boehringer Ingelheim International GmbH Utilisation de matière à fabriquer les comprimés dont on ajuste sélectivement l'humidité dans la production de comprimés mécaniquement stables qui contiennent au moins une substance active formant un hydrate et/ou un adjuvant lié à la stabilité mécanique des comprimés, en particulier des comprimés contenant de l'arginine
WO2014080383A1 (fr) * 2012-11-26 2014-05-30 Ranbaxy Laboratories Limited Composition pharmaceutique d'inhibiteurs de la dipeptidyl-peptidase-iv (dpp-iv) en association avec d'autres antidiabétiques
WO2014080384A1 (fr) 2012-11-26 2014-05-30 Ranbaxy Laboratories Limited Composition pharmaceutique de linagliptine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106138059A (zh) * 2015-03-27 2016-11-23 天津汉瑞药业有限公司 一种稳定的利格列汀药物组合物
EP3156048A1 (fr) * 2015-10-13 2017-04-19 Galenicum Health S.L. Composition pharmaceutique stable de linagliptine sous forme de comprimé à libération immédiate

Also Published As

Publication number Publication date
EP3723761A4 (fr) 2021-06-30
EP3723761A2 (fr) 2020-10-21
TR201720515A2 (tr) 2019-07-22
WO2019203755A2 (fr) 2019-10-24
CA3085455A1 (fr) 2019-10-24
CA3085455C (fr) 2022-08-16

Similar Documents

Publication Publication Date Title
SG11202106534RA (en) Claudin18.2 binding moieties and uses thereof
EP4233846A3 (fr) Formulations pharmaceutiques
IL283539A (en) 3,3-difluoroallylamines or their salts and pharmaceutical preparations containing them
MX2017016802A (es) Formulaciones farmaceuticas.
IL287905A (en) A pharmaceutical preparation containing brexanolone, gnaxolone or zoranolone and its use
USD792319S1 (en) Anchor
EP3894408A4 (fr) Triazolopyridin-3-ones ou leurs sels et compositions pharmaceutiques les comprenant
IL284765A (en) 8,1-naphthyridinone compounds and their uses
EP3731837A4 (fr) Combinaison contenant de la linagliptine et de la metformine
EP3539978A4 (fr) Fragment de nkx3.2 et composition pharmaceutique le comprenant en tant que principe actif
ZA201905763B (en) Liposomal compositions and solid oral dosage forms comprising the same
GB201900665D0 (en) 06557607002
GB202015822D0 (en) 66.123.142648/01
WO2019203755A3 (fr) Forme pharmaceutique orale solide comprenant de la linagliptine
EP3793586A4 (fr) Variants de type 1 du récepteur du complément soluble et utilisations associées
IL282999A (en) 4,3,1-oxadiazolone compound and drug
IL288990A (en) Meters drug succinate, preparations containing the drug meters succinate and its uses
EP3735394A4 (fr) Compositions isotopiques ii
PL4021900T3 (pl) 2,2,6-trimetylo-4,5-dihydro-3h-oksepina jako składnik aromatowy
GB201917427D0 (en) The flylead
GB201916822D0 (en) The degravitator
GB202013791D0 (en) Tidysqueeze 9
GB201819687D0 (en) Mrbr.5
GB201904750D0 (en) The dehydrometer
GB201902293D0 (en) The hangit

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 3085455

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018914956

Country of ref document: EP

Effective date: 20200715

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18914956

Country of ref document: EP

Kind code of ref document: A2